//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы

48//

Cell Carcinoma Database Consortium (IMDC) [ASCO GU 581]. J Clin Oncol. 2018;36(suppl 6).

Alt A.L. et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117:2873.

Petralia G. et al. Complete metastasectomy is an independent predictor of cancer-specific survival in patients with clinically metastatic renal cell carcinoma. Eur Urol Suppl. 2010;2010:162.

Amiraliev A. et al. Treatment strategy in patients with pulmonary metastases of renal cell cancer. Int Cardio Thor Surg. 2012:S20.

Fuchs B. et al. Solitary bone metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res. 2005:187.

Bennani О. et al. Brain metastasis from renal cell carcinoma. Neurochirurgie. 2014;60:12–16.

Fokas E. et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol. 2010;186:210.

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999;353:14.

Coppin C. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev. 2005:CD001425.

Escudier B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103.

Motzer R.J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115.

Hudes G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271.

Escudier B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125.

//Краткое руководство по ведению пациентов с онкологическими заболеваниями мочеполовой системы

//49

Sternberg C.N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061.

Motzer R.J. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722.

Escudier B.J. et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) – PISCES study, NCT 01064310. J Clin Oncol. 2012;30.

Rini B.I. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931.

Motzer R.J. et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552.

Hudes G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271.

Hutson T.E. et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32:760.

Motzer R.J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449.

Motzer R.J. et al. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2013:31.

Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi: 10.1056/NEJMoa1510665. PMID: 26406148.

Escudier B., Sharma P., McDermott D.F. et al. CheckMate 025 Randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus